1. Mid-term outcomes of cardiovascular surgery for patients with Marfan syndrome
- Author
-
Mika Noda, Hiroshi Ishikawa, Koji Hattori, Yasushi Takagi, Masato Tochii, Kentaro Amano, Michiko Ishida, Yusuke Sakurai, Yoshiro Higuchi, and Takashi Watanabe
- Subjects
Adult ,Male ,Reoperation ,musculoskeletal diseases ,Pulmonary and Respiratory Medicine ,Marfan syndrome ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Aortic Valve Insufficiency ,Marfan Syndrome ,Young Adult ,Surgical oncology ,medicine ,Humans ,cardiovascular diseases ,skin and connective tissue diseases ,Emergency Treatment ,Retrospective Studies ,Aortic dissection ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Aortic Aneurysm ,Surgery ,Cardiac surgery ,Survival Rate ,Aortic Dissection ,Patient population ,Treatment Outcome ,Cardiothoracic surgery ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Cardiovascular manifestations determine the prognosis and survival of patients with Marfan syndrome (MFS). We assessed the early and mid-term outcomes of cardiovascular surgery for this patient population.We conducted a retrospective evaluation of patients with MFS who underwent surgery in our department. The endpoint was the requirement for a second cardiovascular surgery, and death from any cause.From February 2002 to March 2013, we performed 24 surgeries on 13 patients with MFS. At the time of initial surgery, the patients' aged ranged from 19 to 64 years of age (mean 34.7 ± 11.3 years) and included 5 men (38.5 %). Five of 13 initial surgeries (38.5 %) were emergencies. Seven patients (53.8 %) presented with aortic dissection at initial surgery, and one of the remaining six patients suffered from new aortic dissection during follow-up. Eight patients (61.5 %) underwent a second surgery, and a second surgery was not required for 100, 75.0, and 53.6 % of patients at 1, 3, and 5 years, respectively. The mean time interval between the first and the second surgeries was 52.8 ± 28.2 months. No patient died while hospitalized, and three subsequently died from unknown causes. Survival rates were 100, 90.9 and 64.9 % at 3, 5, and 7 years, respectively.Although we obtained satisfactory early outcomes for patients with MFS, there were three late deaths from unknown causes. Therefore, we recommend that patients with MFS should remain under close surveillance.
- Published
- 2014